Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Glaukos Corporation GKOS

Healthcare Medical Devices
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow... see more

Recent & Breaking News (NYSE:GKOS)

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire November 3, 2025

Glaukos Announces Third Quarter 2025 Financial Results

Business Wire October 29, 2025

Glaukos Announces FDA Approval of Epioxa(TM)

Business Wire October 20, 2025

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Business Wire October 14, 2025

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Business Wire October 8, 2025

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Business Wire September 25, 2025

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Business Wire August 13, 2025

Glaukos Announces Second Quarter 2025 Financial Results

Business Wire July 30, 2025

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Business Wire July 9, 2025

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Business Wire June 25, 2025

NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

PR Newswire June 25, 2025

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Business Wire June 25, 2025

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire May 13, 2025

Glaukos Announces First Quarter 2025 Financial Results

Business Wire April 30, 2025

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Business Wire April 23, 2025

Glaukos Announces the Release of its 2024 Sustainability Report

Business Wire April 16, 2025

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Business Wire April 9, 2025

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Business Wire March 11, 2025

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa(TM)

Business Wire February 24, 2025

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Business Wire February 20, 2025